This invention relates to the treatment of androgen receptor-positive breast cancer in a subject, for example a female subject. Accordingly, this invention provides methods of: a) treating a subject suffering from breast cancer； b) treating a subject suffering from metastatic breast cancer； c) treating a subject suffering from refractory breast cancer； d) treating a subject suffering from AR-positive breast cancer； e) treating a subject suffering from AR-positive refractory breast cancer； f) treating a subject suffering from AR-positive metastatic breast cancer； g) treating a subject suffering from AR-positive and ER-positive breast cancer； h) treating a subject suffering from triple negative breast cancer； i) treating a subject suffering from advanced breast cancer； j) treating a subject suffering from breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments； k) treating, preventing, suppressing or inhibiting metastasis in a subject suffering from breast cancer； l) prolonging survival of a subject with breast cancer, and/or m) prolonging the progression-free survival of a subject with breast cancer； comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound, comprising administering to the subject a therapeutically effective amount of a SARM compound of this invention.
